Pilot Study Comparing the Safety and Efficacy of Two Dosing Regimens of TP-03 for the Treatment of MGD
Status:
Not yet recruiting
Trial end date:
2023-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the safety and efficacy of TP-03, 0.25%, an eyedrop,
BID vs TID dosing regimens for the treatment of meibomian gland dysfunction in patients with
Demodex lid infestation.